Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.56 |
| ▸ | PI4KA | P42356 | 10/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | AHCY | P23526 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9120 | 0.83 | ADORA2A (0.59) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL20208091 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL21127807 | 0.79 | ADORA2A (0.34) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL22326706 | 0.79 | FDPS (0.41) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL18521272 | 0.79 | ADORA2A (0.34) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28004916 | 0.79 | ADORA2A (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL48453 | 0.79 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28004601 | 0.79 | ADORA2A (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9621206 | 0.78 | GSK3B (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28601746 | 0.78 | ADORA2A (0.49) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219717-A2 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| EP-4115908-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| CN-104513241-B | New regadenoson intermediate, preparation method and application thereof | 浙江海正药业股份有限公司 | 2017-02-08 | — | — | CN | disclosed |
| CN-104513241-A | New regadenoson intermediate, preparation method and application thereof | ZHEJIANG HISUN PHARM CO LTD | 2015-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ADORA2A 385/4885ADORA1 446/4885PI4KA 2825/4885 |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA2A 73/4885ADORA1 32/4885PI4KA 2270/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | ADORA2A 385/4885ADORA1 446/4885PI4KA 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.